Ten Stocks Trending on Discord for Friday August 19, 2022: BBBY, ENDP, AXSM, MNMD, APDN, VTGN, BBIG, TBLT, PETZ, PRTY
$APDN
$AXSM
$BBBY
$BBIG
Other Consumer Services
Consumer Discretionary
Biotechnology: Pharmaceutical Preparations
Health Care
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Company | Date | Price Target | Rating | Analyst |
|---|---|---|---|---|
| 2/24/2026 | $230.00 | Outperform | Wolfe Research | |
| 1/8/2026 | $204.00 | Overweight → Equal-Weight | Morgan Stanley | |
| 12/17/2025 | $0.90 | Buy → Hold | Jefferies | |
| 12/17/2025 | Buy → Hold | Maxim Group | ||
| 12/17/2025 | Outperform → Mkt Perform | William Blair | ||
| 12/17/2025 | $1.00 | Buy → Hold | Stifel | |
| 10/13/2025 | $28.00 | Buy | Needham | |
| 10/1/2025 | $179.00 | Buy | B. Riley Securities |
BEIJING, March 18, 2026 /PRNewswire/ -- TDH Holdings, Inc. (NASDAQ:PETZ) ("TDH" or the "Company"), a PRC-based company that is an owner, operator and manager of commercial real estate properties, announced that it has received a letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") notifying the Company that it is not in compliance with Nasdaq's independent director and audit committee requirements as set forth in Listing Rule 5605. This press release is issued pursuant to Nasdaq Listing Rule 5810(b), which requires disclosure of receipt of a deficiency notification. The notification has no immediate effect on the listing of the Company's common shares,
Vistagen (NASDAQ:VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced that the Company will participate in the following upcoming March investor conferences: Leerink Healthcare Conference Date: March 9-11, 2026 Format: One-on-one meetings Location: Miami, FL Stifel 2026 Virtual CNS Forum Date: March 17, 2026 Format: Fireside chat with President and CEO Shawn Singh and one-on-one meetings Time: 9:00 AM EDT Location: Virtual The Stifel CNS presentation will be accessible via a live webcast on the "Events" page in the Inves
Issued on behalf of Helus PharmaVANCOUVER, BC, Feb. 26, 2026 /CNW/ -- USA News Group News Commentary – The first psilocybin compound to achieve two positive Phase 3 results in treatment-resistant depression cleared that milestone this week, signaling a potential shift in how regulators and investors view psychedelic-based psychiatry[1]. The pathway is widening at the federal level, where the Drug Enforcement Administration raised its 2026 psilocybin production quota by 67%[2]. Five companies are working to translate that momentum into approved treatments: Helus Pharma (NASDAQ:HELP), Compass Pathways (NASDAQ:CMPS), Relmada Therapeutics (NASDAQ:RLMD), Alto Neuroscience (NYSE:ANRO), and Axsome
3 - TDH Holdings, Inc. (0001684425) (Issuer)
3 - TDH Holdings, Inc. (0001684425) (Issuer)
3 - TDH Holdings, Inc. (0001684425) (Issuer)
8-K - Vistagen Therapeutics, Inc. (0001411685) (Filer)
6-K - TDH Holdings, Inc. (0001684425) (Filer)
PRE 14A - BED BATH & BEYOND, INC. (0001130713) (Filer)
Submission status for AXSOME THERAPEUTICS, INC.'s drug AUVELITY (ORIG-1) with active ingredient DEXTROMETHORPHAN HYDROBROMIDE AND BUPROPION HYDROCHLORIDE has changed to 'Approval' on 08/18/2022. Application Category: NDA, Application Number: 215430, Application Classification: Type 3 - New Dosage Form and Type 4 - New Combination
Wolfe Research initiated coverage of Axsome Therapeutics with a rating of Outperform and set a new price target of $230.00
Morgan Stanley downgraded Axsome Therapeutics from Overweight to Equal-Weight and set a new price target of $204.00
Jefferies downgraded VistaGen from Buy to Hold and set a new price target of $0.90
4 - BED BATH & BEYOND, INC. (0001130713) (Issuer)
4 - Axsome Therapeutics, Inc. (0001579428) (Issuer)
4 - Mind Medicine (MindMed) Inc. (0001813814) (Issuer)
SC 13G/A - Toughbuilt Industries, Inc (0001668370) (Subject)
SC 13G - APPLIED DNA SCIENCES INC (0000744452) (Subject)
SC 13G/A - Vistagen Therapeutics, Inc. (0001411685) (Subject)
Strategic hire strengthens focus on growth, margin expansion, and whole-home execution entering 2026 MURRAY, Utah and NASHVILLE, Tenn., Dec. 9, 2025 /PRNewswire/ -- Bed Bath & Beyond, Inc. (NYSE:BBBY) and The Brand House Collective, Inc. (NASDAQ:TBHC) today announced that Nora Gomez has been appointed Chief Merchandising Officer for Bed Bath & Beyond and its family of brands, driving unified product strategy and accountability across the entire portfolio. Gomez is a proven retail leader with over 20 years of experience in assortment strategy, global sourcing, and multi-channel
Vistagen (NASDAQ:VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced the appointment of Nick Tressler as Chief Financial Officer (CFO), effective today, December 1, 2025. "I am excited to welcome Nick to Vistagen as our CFO. His financial and strategic acumen and extensive operational experience in the biopharmaceutical industry will be instrumental as we accelerate into our next phase," said President and Chief Executive Officer of Vistagen, Shawn Singh. "I look forward to his contributions to our leadership team and the po
Mr. Edick brings extensive industry experience across product development, commercial launch, and growth strategy Vistagen (NASDAQ:VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced the appointment of Mr. Paul Edick to its Board of Directors ("Board"). Following the appointment of Mr. Edick, Vistagen's Board will be comprised of seven directors. Mr. Edick will serve on the Audit Committee and the Compensation Committee of the Board. "We are pleased to welcome Mr. Edick to our Board of Directors," said Maggie FitzPatrick,
Q4 Reflects Strengthening Revenue Trends, Sustained Margin Expansion and a $118 Million Year-Over-Year Improvement in Operating Cash Flow Use Bed Bath & Beyond, Inc. (NYSE:BBBY), owner of Bed Bath & Beyond, Overstock, buybuy BABY, Kirkland's Home and a blockchain asset portfolio, today reported financial results for the fourth quarter and full year ended December 31, 2025. The Company delivered its eighth consecutive quarter of measurable improvement toward profitability, reflecting continued margin expansion, disciplined cost management and consistent progress across key operating metrics. The Company has successfully built the base of its business through disciplined retail executio
Total 4Q and full year 2025 net product revenue of $196.0 million and $638.5 million, respectively,representing 65% and 66% year-over-year growth AUVELITY® 4Q and full year 2025 net product sales of $155.1 million and $507.1 million, respectively,representing 68% and 74% year-over-year growth SUNOSI® 4Q and full year 2025 net product revenue of $36.7 million and $124.8 million, respectively,representing 40% and 32% year-over-year growth SYMBRAVO® 4Q and full year 2025 net product sales of $4.1 million and $6.6 million, respectively sNDA for AXS-05 for the treatment of Alzheimer's disease agitation granted Priority Review with PDUFAtarget action date of April 30, 2026 Acquired AXS-17, a novel
PALISADE-4 Phase 3 Trial of fasedienol for acute treatment of Social Anxiety Disorder proceeding, with topline results from the randomized portion of the trial expected in the first half of 2026 Vistagen (NASDAQ:VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today reported financial results for its fiscal year 2026 third quarter ended December 31, 2025, and provided a corporate update. "We have reviewed available data from PALISADE-3 and implemented moderate refinements, including retraining, site rationalization, and operational en